At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Bimekizumab and Placebo for Chronic Plaque Psoriasis. Completed, enrolled 49 participants across 8 sites in 4 countries.
Detailed Summary
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesAustralia, Canada, Moldova, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedJan 19, 2017
Enrollment StartDec 27, 2016
Primary CompletionDec 11, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.5 years ago
Interventions
Bimekizumabdrug
Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
Placeboother
Subjects will receive injections of Placebo.